Research programme: inhaled cystic fibrosis therapeutics - Vectura/Chiesi

Drug Profile

Research programme: inhaled cystic fibrosis therapeutics - Vectura/Chiesi

Latest Information Update: 04 Nov 2017

Price : *
* Final gross price and currency may vary according to local VAT and billing address.

At a glance

  • Originator Activaero GmbH; Chiesi Farmaceutici
  • Developer Chiesi Farmaceutici; Vectura
  • Class
  • Mechanism of Action
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • New Molecular Entity Yes

Highest Development Phases

  • No development reported Cystic fibrosis

Most Recent Events

  • 04 Nov 2017 No recent reports of development identified for preclinical development in Cystic-fibrosis in Italy (Inhalation)
  • 13 Mar 2014 Activaero GmbH has been acquired by Vectura
  • 09 Sep 2013 Preclinical trials in Cystic fibrosis in Italy (Inhalation)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top